These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 590343)

  • 1. A pharmacologic comparison of 3,4-methylenedioxyamphetamine and LSD in the chronic spinal dog.
    Nozaki M; Vaupel DB; Martin WR
    Eur J Pharmacol; 1977 Dec; 46(4):339-49. PubMed ID: 590343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacological comparison of 3-methoxy-4,5-methylenedioxyamphetamine and LSD in the dog.
    Nozaki M; Vaupel DB; Bright LD; Martin WR
    Drug Alcohol Depend; 1978 May; 3(3):153-63. PubMed ID: 668489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose and cross tolerance studies of beta-phenethylamine, d-amphetamine and LSD in the chronic spinal dog.
    Vaupel DB; Nozaki M; Martin WR; Bright LD
    Eur J Pharmacol; 1978 Apr; 48(4):431-7. PubMed ID: 648586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDA and DOM: substituted amphetamines that do not produce amphetamine-like discriminative stimuli in the rat.
    Shannon HE
    Psychopharmacology (Berl); 1980; 67(3):311-2. PubMed ID: 6770411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The identification of LSD-like hallucinogens using the chronic spinal dog.
    Martin WR; Vaupel DB; Nozaki M; Bright LD
    Drug Alcohol Depend; 1978 Mar; 3(2):113-23. PubMed ID: 272982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDA: an agent that produces stimulus effects similar to those of 3,4-DMA, LSD and cocaine.
    Glennon RA; Young R
    Eur J Pharmacol; 1984 Mar; 99(2-3):249-50. PubMed ID: 6145599
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex.
    Gresch PJ; Smith RL; Barrett RJ; Sanders-Bush E
    Neuropsychopharmacology; 2005 Sep; 30(9):1693-702. PubMed ID: 15756304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of CNS tryptaminergic processes and the action of LSD-like hallucinogens.
    Martin WR; Sloan JW
    Pharmacol Biochem Behav; 1986 Feb; 24(2):393-9. PubMed ID: 3006088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological and toxicological effects of beta-3,4-methylenedioxyamphetamine isomers.
    Marquardt GM; DiStefano V; Ling LL
    Toxicol Appl Pharmacol; 1978 Sep; 45(3):675-83. PubMed ID: 725923
    [No Abstract]   [Full Text] [Related]  

  • 11. Responses of the flexor reflex to LSD, tryptamine, 5-hydroxytryptophan, methoxamine, and d-amphetamine in acute and chronic spinal rats.
    Nozaki M; Bell JA; Vaupel DB; Martin WR
    Psychopharmacology (Berl); 1977 Nov; 55(1):13-8. PubMed ID: 414256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of anesthesia and phenoxybenzamine on responses of dogs to IV subtoxic doses of 3,4-methylenedioxyamphetamine (MDA).
    Waters IW; Catravas JD; Davis WM
    Arch Int Pharmacodyn Ther; 1986 Jun; 281(2):240-51. PubMed ID: 3753103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of an animal behavioral model in studying the duration of action of LSD and the onset and duration of tolerance to LSD in the cat.
    Trulson ME; Jacobs BL
    Brain Res; 1977 Aug; 132(2):315-26. PubMed ID: 890483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic effects of D-lysergic acid diethylamide (LSD) and its derivatives in rabbits and rats.
    Hashimoto H; Hayashi M; Nakahara Y; Niwaguchi T; Ishii H
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):314-21. PubMed ID: 303504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
    Marona-Lewicka D; Thisted RA; Nichols DE
    Psychopharmacology (Berl); 2005 Jul; 180(3):427-35. PubMed ID: 15723230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A behavioral comparison of Nexus, cathinone, BDB, and MDA.
    Bronson ME; Jiang W; DeRuiter J; Clark CR
    Pharmacol Biochem Behav; 1995; 51(2-3):473-5. PubMed ID: 7667371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Separation of tolerance to the behavioral effects of LSD from changes in serotonin receptor binding in cats.
    Trulson ME
    Eur J Pharmacol; 1985 May; 111(3):385-8. PubMed ID: 4018133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats.
    Trulson ME; Heym J; Jacobs BL
    Brain Res; 1981 Jun; 215(1-2):275-93. PubMed ID: 6114779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs that antagonize limb flick behavior induced by D-lysergic acid diethylamide (LSD) in cats.
    Haigler HJ; Spring DD
    Psychopharmacology (Berl); 1979 Jun; 64(1):31-4. PubMed ID: 113828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance and limited cross-tolerance to the effects of N, N-dimethyltryptamine (DMT) and lysergic acid diethylamide-25 (LSD) on food-rewarded bar pressing in the rat.
    Kovacic B; Domino EF
    J Pharmacol Exp Ther; 1976 Jun; 197(3):495-502. PubMed ID: 1064726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.